ArticleJournal of thrombosis and haemostasis : JTH2022
Maintaining flippase activity in procoagulant platelets is a novel approach to reducing thrombin generation.
Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Procoagulant platelets: linking coagulation and thromboinflammation in cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Surface cues shape procoagulant properties of amyloidogenic microclots.Cell death & disease · 2026Review
- rFVIIIa-platelet binding enhances platelet procoagulant activity independently of thrombin generation.Blood vessels, thrombosis & hemostasis · 2026Article
- Procoagulant Effects of Isothiazolinone Biocides, Benzisothiazolinone and Octylisothiazolinone in Platelets.Toxics · 2026Article
- Engineered Fluorescent Variants of Lactadherin C2 Domain for Phosphatidylserine Detection in Flow Cytometry.Biomolecules · 2025Article
- Interplay Between Metabolic Pathways and Increased Oxidative Stress in Human Red Blood Cells.Cells · 2024Review
- Phosphatidylserine: A Novel Target for Ischemic Stroke Treatment.Biomolecules · 2024Review
- Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity.International journal of molecular sciences · 2023Article
- Procoagulant platelets: novel players in thromboinflammation.American journal of physiology. Cell physiology · 2022Review
- Procoagulant platelet sentinels prevent inflammatory bleeding through GPIIBIIIA and GPVI.Blood · 2022Article
- Maintaining flippase activity in procoagulant platelets is a novel approach to reducing thrombin generation.Journal of thrombosis and haemostasis : JTH · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDuring thrombosis, procoagulant platelets expose phosphatidylserine (PS), which enhances local thrombin generation. Reducing platelet PS exposure could be a novel anti-thrombotic approach. PS is confined to the inner leaflet of the plasma membrane in unstimulated platelets by ATP-dependent "flippase" activity. Ca
objectivesTo determine the mechanism by which R5421 reduces platelet PS exposure.
methodsWashed human platelets were stimulated with the Ca RESULTS AND
conclusionsR5421 reduced the extent of A23187-stimulated platelet PS exposure, as demonstrated with annexin V or lactadherin binding. R5421 also maintained flippase activity in procoagulant platelets. Although R5421 appeared to inhibit scramblase activity in procoagulant platelets, it did not once the flippase had been inhibited, demonstrating that scramblase activity is not directly inhibited. Furthermore, R5421 inhibited the contribution of A23187-stimulated platelets to thrombin generation. Together these data demonstrate that R5421 reduces the extent of PS exposure in procoagulant platelets by maintaining flippase activity. Maintaining flippase activity in procoagulant platelets is a novel and effective approach to reducing thrombin generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.